Gemvaxlink Co., Ltd. announced that it has received KRW 29.099978456 billion in funding from GemVax&KAEL Co.,Ltd., Keonyang Co., Ltd., Wingbridge I&D Co., Ltd., Kaffaint Co. Ltd and other investors
March 17, 2024
Share
On March 18, 2024, Gemvaxlink Co., Ltd., closed the transaction. The company announced that it has issued 9,505,982 common for the gross proceeds of KRW 12,699,991,952 in its second and final tranche closing.
GemVax & KAEL Co.,Ltd is a Korea-based company mainly engaged in the manufacture of pollution control equipment used in semiconductor manufacturing processes. The Company and its subsidiaries are engaged in the three categories of businesses: pollution control business, which manufactures chemical air (CA) filters, gas scrubbers, resins, coating resins and other environmental equipments and systems; anticancer and anti-inflammation business, which engages in development of cancer vaccines for infectious diseases, such as acquired immune deficiency syndrome (AIDS) and anti-inflammations, and IT business which mainly produces liquid crystal display (LCD) modules. The Company distributes its products within domestic market and to overseas markets.
Gemvaxlink Co., Ltd. announced that it has received KRW 29.099978456 billion in funding from GemVax&KAEL Co.,Ltd., Keonyang Co., Ltd., Wingbridge I&D Co., Ltd., Kaffaint Co. Ltd and other investors
GEMVAX&KAEL CO.,LTD. 
